Reilly L, Magkrioti C, Mduluza T, Cavanagh D R, Mutapi F
Institute for Immunology and Infection Research, School of Biological Sciences, Ashworth Laboratories, University of Edinburgh, Edinburgh, UK.
BMC Infect Dis. 2008 Nov 17;8:158. doi: 10.1186/1471-2334-8-158.
The overlapping geographical and socio-economic distribution of malaria and helminth infection has led to several studies investigating the immunological and pathological interactions of these parasites. This study focuses on the effect of treating schistosome infections on natural human immune responses directed against plasmodia merozoite surface proteins MSP-1 (DPKMWR, MSP1(19)), and MSP-2 (CH150 and Dd2) which are potential vaccine candidates as well as crude malaria (schizont) and schistosome (whole worm homogenate) proteins.
IgG1 and IgG3 antibody responses directed against Schistosoma haematobium crude adult worm antigen (WWH) and Plasmodium falciparum antigens (merozoite surface proteins 1/2 and schizont extract), were measured by enzyme linked immunosorbent assay (ELISA) in 117 Zimbabweans (6-18 years old) exposed to S. haematobium and P. falciparum infection. These responses were measured before and after anti-helminth treatment with praziquantel to determine the effects of treatment on anti-plasmodial/schistosome responses.
There were no significant associations between antibody responses (IgG1/IgG3) directed against P. falciparum and schistosomes before treatment. Six weeks after schistosome treatment there were significant changes in levels of IgG1 directed against schistosome crude antigens, plasmodia crude antigens, MSP-1(19), MSP-2 (Dd2), and in IgG3 directed against MSP-1(19). However, only changes in anti-schistosome IgG1 were attributable to the anti-helminth treatment.
There was no association between anti-P. falciparum and S. haematobium antibody responses in this population and anti-helminth treatment affected only anti-schistosome responses and not responses against plasmodia crude antigens or MSP-1 and -2 vaccine candidates.
疟疾和蠕虫感染在地理和社会经济分布上相互重叠，这促使多项研究对这些寄生虫的免疫和病理相互作用进行调查。本研究聚焦于治疗血吸虫感染对针对疟原虫裂殖子表面蛋白MSP-1（DPKMWR，MSP1(19)）和MSP-2（CH150和Dd2）的天然人类免疫反应的影响，这些蛋白是潜在的疫苗候选物，同时还研究了粗制疟疾（裂殖体）和血吸虫（全虫匀浆）蛋白。
采用酶联免疫吸附测定（ELISA）法，检测了117名（6至18岁）同时感染埃及血吸虫和恶性疟原虫的津巴布韦人针对埃及血吸虫成虫粗抗原（WWH）以及恶性疟原虫抗原（裂殖子表面蛋白1/2和裂殖体提取物）的IgG1和IgG3抗体反应。在用吡喹酮进行抗蠕虫治疗前后测量这些反应，以确定治疗对抗疟原虫/血吸虫反应的影响。
治疗前，针对恶性疟原虫和血吸虫的抗体反应（IgG1/IgG3）之间无显著关联。血吸虫治疗六周后，针对血吸虫粗抗原、疟原虫粗抗原、MSP-1(19)、MSP-2（Dd2）的IgG1水平以及针对MSP-1(19)的IgG3水平发生了显著变化。然而，只有抗血吸虫IgG1的变化可归因于抗蠕虫治疗。
该人群中抗恶性疟原虫和抗埃及血吸虫抗体反应之间无关联，抗蠕虫治疗仅影响抗血吸虫反应，而不影响针对疟原虫粗抗原或MSP-1和-2疫苗候选物的反应。
